ESR1 and cancer: In fact, for most biomarkers, the probability of a patient group responding increases with the increasing positivity of the biomarker, e.g., patients with strongly ER-positive cancers are more likely to respond to endocrine therapy than weakly ER-positive cancers, and this applies to many biomarkers, including TILs and PDL1.